US Patent 6,858,576: Claim Scope, Expiration, and Exendin Patent Landscape

US Patent 6,858,576 covered methods of reducing gastric motility and delaying gastric emptying with exendins, including exendin-3, exendin-4, and specified exendin analogs. The patent issued February 22, 2005, and its 20-year term from the relevant nonprovisional filing date ended April 20, 2021. The patent is therefore expired and no longer creates a current US infringement barrier for exenatide or other exendin-based products. Its historical importance was greater than its present commercial value because it targeted a physiologic effect associated with exenatide rather than the principal diabetes indication.

What does US Patent 6,858,576 cover?

The patent covers administering an exendin or exendin analog to reduce gastric motility or delay gastric emptying. The claims are method-of-treatment claims rather than claims directed to:

The exendin molecule itself;
A formulation;
A delivery device;
A manufacturing process;
A specific dose or dosing schedule; or
A product approved for diabetes treatment.

The claim set has four principal coverage groups.

Claim group	Claims	Covered subject matter
Native exendins	1-8	Reducing gastric motility or delaying gastric emptying with an exendin
Defined exendin analogs	9-16	Same methods using broad Markush-defined peptide analogs
Exendin-4	17-22	Reducing gastric motility or delaying gastric emptying specifically with exendin-4
Diagnostic and disease settings	5-8, 13-16, 19-22	Gastrointestinal diagnostic procedures, radiological examinations, MRI, or gastrointestinal disorders

Exendin-4 is the active ingredient known commercially as exenatide. The patent claims use the terms “exendin” and “exendin analog,” while modern regulatory materials generally identify the active pharmaceutical ingredient as exenatide.

When did US Patent 6,858,576 expire?

US Patent 6,858,576 expired on April 20, 2021, based on the 20-year patent term calculated from the April 20, 2001 nonprovisional filing date. The patent was not a current US exclusivity right after that date.

Event	Date
Priority date	April 21, 2000
US nonprovisional filing	April 20, 2001
US publication	January 17, 2002
Patent grant	February 22, 2005
Expected statutory expiration	April 20, 2021
Current status	Expired

The one-day difference between the provisional priority date and the nonprovisional filing date matters because US patent term generally runs from the earliest effective nonprovisional application, not from a provisional application. The patent is therefore relevant as historical prior art and as part of the development history of exenatide, but it does not support a present-day infringement suit.

Source: US Patent and Trademark Office, Patent Center; US Patent 6,858,576.

How broad are claims 1 through 8?

Claims 1 and 2 are broad functional method claims. Claim 1 covers administering an amount of an exendin effective to reduce gastric motility. Claim 2 covers administering an amount effective to delay gastric emptying.

The claims do not require:

A particular exendin sequence;
A particular route of administration;
A specified dose;
A specified duration of treatment;
A diabetes diagnosis;
A particular formulation; or
A measured percentage reduction in gastric motility.

Claims 3 and 4 narrow the active substance to exendin-3 or exendin-4. Claims 5 through 7 narrow the patient context to gastrointestinal diagnostic procedures, radiological examinations, and MRI. Claim 8 applies where the subject suffers from a gastrointestinal disorder.

The practical scope of claims 1 and 2 depended on proving several elements:

The administered substance was an exendin.
The patient was a subject “in need thereof.”
The administration was intended to reduce gastric motility or delay gastric emptying.
The administered amount was effective for that result.

The functional “effective amount” limitation would have required evidence linking the dose and administration to the claimed physiologic effect. A product label that merely described exenatide’s effects on gastric emptying would not automatically establish infringement. The relevant question would have been whether the accused conduct practiced the claimed method, including the required purpose or treatment context.

What is the scope of the exendin analog Markush claims?

Claims 9 through 12 cover methods using peptide compounds defined by a large Markush formula. The formula preserves the general exendin backbone while permitting substitutions at multiple positions.

The analog claims allow variation in:

N-terminal residues;
Aromatic residues, including phenylalanine, tyrosine, and naphthylalanine;
Hydrophobic residues such as leucine, isoleucine, valine, methionine, and pentylglycine;
Acidic residues, including aspartic acid and glutamic acid;
Proline-related residues, including homoproline, hydroxyproline, thioproline, and N-substituted amino acids; and
The C-terminal group, which may be hydroxyl or amide.

The proviso excludes the exact structures of exendin-3 and exendin-4. That exclusion prevents claims 9 through 12 from independently claiming the native peptides already covered by claims 3, 4, and 17 through 18.

The two analog groups differ in breadth:

Feature	Claims 9 and 11	Claims 10 and 12
Xaa1	His, Arg, or Tyr	His or Arg
Xaa2	Ser, Gly, Ala, or Thr	Ser or Gly
Xaa4	Phe, Tyr, or naphthylalanine	Phe or naphthylalanine
Xaa8/Xaa9	Broad hydrophobic options	Leu or pentylglycine
Xaa11	Broad hydrophobic options	Ile, Val, or tert-butylglycine
Xaa13	Trp, Phe, Tyr, or naphthylalanine	Trp or Phe
Proline-related residues	Broadest set	Pro, homoproline, or N-methylalanine

Claims 9 and 11 are the broader analog method claims. Claims 10 and 12 are narrower alternatives that reduce the number of permitted substitutions.

Because these claims are expired, the Markush breadth now has primarily technical and prior-art significance. It may remain relevant when evaluating the validity or scope of later patents claiming particular exendin analogs, stabilized peptides, or long-acting GLP-1 receptor agonists.

What do claims 17 and 18 add?

Claims 17 and 18 are independent claims specifically directed to exendin-4. Claim 17 covers reducing gastric motility, while claim 18 covers delaying gastric emptying.

These claims overlap materially with claims 1 and 2 as applied to exendin-4. Their apparent purpose was to create direct, stand-alone coverage of the clinically important native peptide rather than relying only on the broader term “exendin.”

Claims 19 through 22 add the same diagnostic and gastrointestinal-disorder limitations found elsewhere in the patent:

Claim 19: gastrointestinal diagnostic procedure;
Claim 20: radiological examination;
Claim 21: MRI; and
Claim 22: gastrointestinal disorder.

The MRI claims are narrow in setting but potentially strong in literal scope if a party administered exendin-4 for the purpose of controlling gastric motion during an MRI procedure. They did not, however, cover MRI equipment, imaging software, or a diagnostic protocol that did not administer an exendin.

What patent claims are excluded from US Patent 6,858,576?

The patent does not directly claim the following subject matter:

Exenatide composition claims

A claim to the exendin-4 peptide as a chemical composition would be distinct from a method claim requiring administration for a gastric-motility purpose.

Formulation claims

The patent does not, based on the supplied claims, require or claim:

Injectable microspheres;
Sustained-release exenatide;
A particular buffer;
A particular preservative;
A specific pH;
A depot formulation; or
A particular injection device.

These subjects were addressed in separate exenatide formulation and delivery patent families.

Diabetes treatment claims

The claims do not expressly require treatment of type 2 diabetes, glycemic control, insulin secretion, weight loss, or HbA1c reduction. A diabetes product could have implicated the patent only if the relevant administration was practiced for the claimed gastric-motility or gastric-emptying purpose.

Manufacturing claims

There is no supplied claim to peptide synthesis, recombinant production, purification, conjugation, microsphere manufacture, or fill-finish operations.

What was the FDA and Orange Book status?

Exenatide was approved by the FDA as Byetta in 2005 for improving glycemic control in adults with type 2 diabetes, in combination with diet and exercise and specified oral antidiabetic agents. Extended-release exenatide was later approved as Bydureon.

The FDA approval pathway focused on diabetes treatment, not on reducing gastric motility as a stand-alone indication. The gastric-emptying effect was described as part of exenatide pharmacology and safety information rather than as the principal approved indication.

US Patent 6,858,576 was not the principal composition or formulation patent associated with the Byetta product. The commercially material exenatide patent estate included separate patents directed to the peptide, formulations, extended-release delivery, and related product technology. The Orange Book assessment therefore had to be conducted patent by patent rather than treating all exendin patents as interchangeable.

FDA approval and Orange Book relevance can be summarized as follows:

Issue	Assessment
Approved active ingredient	Exenatide
Principal branded product	Byetta
Extended-release product	Bydureon
Main approved use	Type 2 diabetes
'576 claim type	Method of treatment
Gastric-motility indication approved?	Not the principal FDA indication
Current '576 Orange Book barrier	None, because the patent expired
Current generic challenge significance	Historical only for this patent

FDA, Orange Book, and product labeling records should be read together because a patent can be technically relevant to a drug’s pharmacology without being listed for the approved indication.

Which companies challenged exenatide patent protection?

The major US competitive challenge to exenatide involved generic or follow-on products targeting the branded Byetta and Bydureon estates. Those challenges focused principally on composition, formulation, device, and extended-release technology rather than on the expired gastric-motility claims of US 6,858,576.

The relevant competitive categories were:

Challenger category	Typical target
Generic injectable manufacturers	Immediate-release exenatide
Follow-on peptide manufacturers	Exenatide composition and formulation
Long-acting GLP-1 developers	Extended-release delivery and alternative molecules
Biosimilar developers	Generally not the principal pathway for exenatide
505(b)(2) applicants	Modified delivery systems or dosing regimens

Exenatide is a synthetic peptide drug. A conventional generic route under section 505(j) is more relevant than a biosimilar pathway under the Public Health Service Act. FDA classification and product-specific requirements determine the precise pathway, but the patent risk analysis should not treat exenatide like a monoclonal antibody.

What Paragraph IV risks applied to this patent?

A Paragraph IV certification would have been relevant only while US 6,858,576 was unexpired and listed for a relevant reference product or use. The patent’s method claims created several potential certification issues:

Whether an ANDA product label instructed use for delayed gastric emptying;
Whether the proposed label included a gastric-motility or gastrointestinal diagnostic use;
Whether the use was merely an unavoidable pharmacologic effect of a different labeled treatment;
Whether the claim required a specific physician intent; and
Whether the claim was invalid or not infringed.

A generic applicant could have pursued a “skinny label” strategy by omitting a patented method of use, provided the remaining label did not encourage the patented use. That strategy would have been more difficult if the proposed labeling expressly promoted gastric-emptying effects or gastrointestinal diagnostic use.

Today, the patent cannot generate a new Paragraph IV litigation event because it has expired. Any current exenatide challenge must be evaluated against unexpired patents, regulatory exclusivity, trade secrets, device rights, and manufacturing know-how.

What patent litigation affected US Patent 6,858,576?

The supplied patent claims do not identify a current litigation dispute, and the patent’s expiration eliminates present enforcement risk. Its historical litigation value was limited by the mismatch between the claimed use and the FDA-approved diabetes indication.

The main litigation questions would have been:

Whether the accused label induced administration for delayed gastric emptying.
Whether ordinary diabetes treatment necessarily practiced the claim.
Whether “subject in need thereof” imposed a meaningful limitation.
Whether the claims were enabled across the full Markush analog genus.
Whether the gastric-motility effect was inherent or intended.
Whether a medical practitioner, manufacturer, or seller was the legally relevant actor.

The medical-procedure safe harbor under 35 U.S.C. § 287(c) could have limited remedies against medical practitioners and related health-care entities for certain medical activities. It would not generally eliminate all risk for a drug manufacturer that promoted or supplied a product for a claimed use.

How strong was the patent estate?

Claim strength

The estate had mixed historical strength.

Dimension	Assessment
Literal breadth	Broad for exendin administration
Technical disclosure	Centered on a known pharmacologic effect
Composition protection	Weak because the claims were methods, not compositions
Formulation protection	Absent from the supplied claims
Approved-label relevance	Limited
Diagnostic-use specificity	Narrow but more directly tied to claims
Current enforceability	None after expiration
Markush genus breadth	Broad, with enablement and written-description exposure

Claims 1, 2, 17, and 18 were potentially vulnerable to validity challenges based on prior art showing that exendins or GLP-1 receptor agonists delayed gastric emptying. The patent’s strongest argument would have been that the claimed use, dosage, or diagnostic context was not taught or suggested by earlier references.

The Markush claims presented a separate risk. The number of permitted substitutions could have generated written-description and enablement challenges if the specification did not demonstrate or adequately teach the full genus.

How did this patent compare with other exenatide patents?

Patent category	Typical protection	Commercial significance
Native exendin composition	Exenatide or related peptide sequence	Core active-ingredient protection
Gastric-motility method, US 6,858,576	Delayed gastric emptying and reduced motility	Narrower use-based protection
Immediate-release formulation	Injectable solution, excipients, stability	Byetta product protection
Extended-release formulation	Microspheres, depot systems, release profiles	Bydureon protection
Device patents	Pen injector or delivery components	Product and device lifecycle management
Manufacturing patents	Peptide production and purification	Supply-chain and quality barriers
Later GLP-1 patents	Semaglutide, liraglutide, tirzepatide and related agents	Competitive rather than direct exendin coverage

The '576 patent was therefore an ancillary method patent. It did not replace the core composition and formulation estate that supported commercial exclusivity for Byetta and Bydureon.

What generic launch risks remain after expiration?

Expiration of US 6,858,576 removes one patent-specific barrier but does not establish freedom to launch an exenatide product. Remaining risks historically included:

Unexpired composition patents;
Formulation and sustained-release patents;
Device patents;
Orange Book-listed method patents;
Patent litigation settlements;
Regulatory exclusivity;
Product-specific bioequivalence requirements;
Manufacturing consistency for a complex peptide;
Peptide aggregation and impurity control;
Depot particle-size and release-profile control for long-acting products; and
Trade-secret manufacturing processes.

For immediate-release exenatide, the principal commercial risk shifted toward formulation, device, regulatory, and manufacturing execution after the core method patent expired. For long-acting exenatide, microsphere technology and release kinetics remained more significant than the gastric-motility claims.

What geographic coverage did the patent provide?

US 6,858,576 provided rights only in the United States. Foreign counterparts, if granted, required separate country-by-country term and legal-status analysis. Expiration in the United States did not automatically determine the status of corresponding patents in Europe, Japan, Canada, or other markets.

For global diligence, the relevant analysis includes:

PCT publication and national-phase entries;
Continuation and divisional applications;
Patent-term adjustments;
Supplementary protection certificates in Europe;
Opposition or revocation proceedings;
Local claim scope; and
Country-specific exhaustion and medical-use doctrines.

The US expiration date should not be used as a global freedom-to-operate date.

Key Takeaways

US Patent 6,858,576 claimed methods of reducing gastric motility and delaying gastric emptying with exendins, exendin-4, and defined analogs.
Claims 1, 2, 17, and 18 were the principal native-exendin method claims.
Claims 9 through 12 covered broad Markush-defined exendin analogs but expressly excluded exendin-3 and exendin-4.
The patent did not claim exenatide as a composition, an injectable formulation, a depot system, a device, or a manufacturing process.
Its statutory term ended April 20, 2021.
The patent is expired and does not create current US infringement or Paragraph IV risk.
The commercial exenatide patent landscape was driven more heavily by composition, formulation, extended-release, device, and manufacturing patents.
Exenatide is a peptide drug, so generic 505(j) and follow-on pathways are generally more relevant than a conventional biosimilar analysis.
The patent’s historical strength was reduced by its limited alignment with the FDA-approved diabetes indication.
Current launch diligence must focus on unexpired exenatide patents, Orange Book records, regulatory requirements, manufacturing capability, and product-specific litigation.

FAQs

Could a generic exenatide label still have infringed US Patent 6,858,576?

No. The patent expired in 2021. A label cannot infringe an expired US patent, although the same conduct could be relevant to other unexpired patents.

Did US Patent 6,858,576 protect Byetta’s injectable formulation?

No. The supplied claims are method claims. They do not require the Byetta excipient system, concentration, container, or injection device.

Did the patent cover exenatide’s effect on gastric emptying during diabetes treatment?

Only if the claimed method elements were practiced, including administration for the claimed gastric-motility or gastric-emptying purpose. A pharmacologic effect occurring incidentally during an unrelated labeled use would not automatically establish infringement.

Could the analog claims cover a modified GLP-1 receptor agonist?

Only if the compound satisfied every structural limitation of the claimed exendin analog formula and the method involved the claimed gastric-motility or gastric-emptying use. Most later GLP-1 agonists would require a separate sequence and claim-construction analysis.

Is a biosimilar application required for an exenatide follow-on product?

Usually not in the same manner as for a biologic such as an antibody. Exenatide is a synthetic peptide drug, and the applicable FDA route depends on the product’s formulation, reference-product relationship, and regulatory characteristics.

References

United States Patent and Trademark Office. (2005). US Patent No. 6,858,576, Use of exendins for reducing gastric motility.
United States Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/
U.S. Food and Drug Administration. (2005). Byetta prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2012). Bydureon prescribing information.
35 U.S.C. §§ 154, 271, 287(c).
21 U.S.C. § 355.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0996459	⤷ Start Trial	CA 2007 00034	Denmark	⤷ Start Trial
European Patent Office	0996459	⤷ Start Trial	91342	Luxembourg	⤷ Start Trial
European Patent Office	0996459	⤷ Start Trial	C00996459/01	Switzerland	⤷ Start Trial
European Patent Office	0996459	⤷ Start Trial	0790031-9	Sweden	⤷ Start Trial
European Patent Office	0996459	⤷ Start Trial	464	Finland	⤷ Start Trial
European Patent Office	0996459	⤷ Start Trial	SZ 31/2007	Austria	⤷ Start Trial
Austria	304864	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,858,576

Summary for Patent: 6,858,576